Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Additionally, Dr. Brangman says that the Tdap vaccine, which protects against tetanus, diphtheria and whooping cough, is also ...